Tofacitinib Citrate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Tofacitinib Citrate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
505
Registered trials
615
Result records
3
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Tofacitinib Citrate can convert its Small molecule drug profile and JAK1 x JAK2 x JAK3 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Tofacitinib Citrate (query alias: tofacitinib) |
|---|---|
| Modality / target | Small molecule drug; JAK1 x JAK2 x JAK3; JAK1 inhibitors, JAK2 inhibitors, JAK3 inhibitors |
| Highest global status | Approved |
| Originator | Pfizer Inc. |
| Active developers | Pfizer Europe MA EEIG, Pfizer Inc., PF Prism CV |
The MCP disease footprint includes Oligoarticular Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Ankylosing Spondylitis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07636057 | Phase 4 | Not yet recruiting | 100 | Change in the Disease activity score(DAS 28) |
| NCT07598643 | Phase 2 | Recruiting | 92 | Number and percentage of subjects experiencing treatment-emergent adverse events. |
| NCT07581418 | Not Applicable | Not yet recruiting | 88 | Change in Psoriasis Area and Severity Index (PASI) score |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Tofacitinib: Suppressing Tumor Invasion in Recurrent GBM Patients
Phase 3; n=18; evaluation: not stated. Reported fields: Progression-free Survival (PFS) of the Study Cohort as Defined by RANO Criteria.(Median) = 4 months (95% Confidence Interval, 0 - 24); -; Progression-free Survival (PFS) of the Study Cohort as Defined by RANO Criteria.(Median) = 4 months (95% Confidence Interval, 0 - 24)
CARDIOVASCULAR OUTCOMES IN PHASE 4 TRIALS OF DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN INFLAMMATORY ARTHRITIS AND CONNECTIVE TISSUE DISEASES
Phase 4; n=4; evaluation: Negative. Reported fields: Hypertension = 25.0 % ; Hypertension = 13.0 %
IMPACT OF BODY MASS INDEX ON RESPONSE TO JAK INHIBITORS IN RHEUMATOID ARTHRITIS: AN INDIVIDUAL PATIENT DATA META-ANALYSIS
Phase 3; n=11883; evaluation: Negative. Reported fields: ACR20(class II) = 0.88 Unit
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Tofacitinib Citrate addresses Oligoarticular Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Ankylosing Spondylitis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-05-29 | 宣泰医药与科兴制药达成战略合作：枸橼酸托法替布缓释片出海科威特、墨西哥 | Approved | Financial terms not disclosed |
| 2021-06-28 | Inmagene and TWIB Partner to Develop AC-1101 for Multiple Dermatological Immunological Diseases｜Institute for Biotechnology and Medicine Industry│IBMI | Phase 1 | US$421.0M stated total |
| 2017-12-18 | Pfizer Terminate Co-Promotion and Takeda's Distribution of 'Xeljanz® Tablets 5 mg' in Japan | Phase 3 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Synthesis method of tofacitinib key intermediate”. The milestone feed surfaced a patent-application signal described as “Preparation method of tofacitinib citrate”. The milestone feed surfaced a patent-application signal described as “Topical pharmaceutical composition of tofacitinib nanostructured carrier for the treatment of vitiligo”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
